{"id":"https://openalex.org/W2073701170","doi":"https://doi.org/10.1089/jop.2010.0085","title":"Topical Loteprednol Pretreatment Reduces Cyclosporine Stinging in Chronic Dry Eye Disease","display_name":"Topical Loteprednol Pretreatment Reduces Cyclosporine Stinging in Chronic Dry Eye Disease","alternate_titles":[],"publication_year":2010,"publication_date":"2010-12-06","ids":{"openalex":"https://openalex.org/W2073701170","doi":"https://doi.org/10.1089/jop.2010.0085","mag":"2073701170","pmid":"https://pubmed.ncbi.nlm.nih.gov/21133792"},"language":"en","primary_location":{"id":"doi:10.1089/jop.2010.0085","doi":"https://doi.org/10.1089/jop.2010.0085","is_oa":false,"landing_page_url":"https://doi.org/10.1089/jop.2010.0085","pdf_url":null,"source":{"id":"https://openalex.org/S192126995","display_name":"Journal of Ocular Pharmacology and Therapeutics","issn_l":"1080-7683","issn":["1080-7683","1557-7732","8756-3320"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Ocular Pharmacology and Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2073701170"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078689711","display_name":"John D. Sheppard","orcid":"https://orcid.org/0000-0003-1216-4056","observed_orcids":["https://orcid.org/0000-0003-1216-4056"]},"institutions":[{"id":"https://openalex.org/I156802259","display_name":"Eastern Virginia Medical School","ror":"https://ror.org/056hr4255","country_code":"US","type":"education","lineage":["https://openalex.org/I156802259"]},{"id":"https://openalex.org/I4210140236","display_name":"Virginia Eye Consultants","ror":"https://ror.org/03sys9n92","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210140236"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"John D. Sheppard","raw_affiliation_strings":["Thomas R Lee Center for Ocular Pharmacology, Eastern Virginia Medical School, Norfolk, Virginia","Virginia Eye Consultants and the Department of Ophthalmology, Eastern Virginia Medical School, Norfolk, Virginia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Thomas R Lee Center for Ocular Pharmacology, Eastern Virginia Medical School, Norfolk, Virginia","institution_ids":["https://openalex.org/I156802259"]},{"raw_affiliation_string":"Virginia Eye Consultants and the Department of Ophthalmology, Eastern Virginia Medical School, Norfolk, Virginia","institution_ids":["https://openalex.org/I156802259","https://openalex.org/I4210140236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059177443","display_name":"Stephen V. Scoper","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I156802259","display_name":"Eastern Virginia Medical School","ror":"https://ror.org/056hr4255","country_code":"US","type":"education","lineage":["https://openalex.org/I156802259"]},{"id":"https://openalex.org/I4210140236","display_name":"Virginia Eye Consultants","ror":"https://ror.org/03sys9n92","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210140236"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Stephen V. Scoper","raw_affiliation_strings":["Virginia Eye Consultants and the Department of Ophthalmology, Eastern Virginia Medical School, Norfolk, Virginia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Virginia Eye Consultants and the Department of Ophthalmology, Eastern Virginia Medical School, Norfolk, Virginia","institution_ids":["https://openalex.org/I156802259","https://openalex.org/I4210140236"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109029073","display_name":"Sandeep S. Samudre","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I156802259","display_name":"Eastern Virginia Medical School","ror":"https://ror.org/056hr4255","country_code":"US","type":"education","lineage":["https://openalex.org/I156802259"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sandeep Samudre","raw_affiliation_strings":["Pharmacology Section, Department of Physiologic Sciences, Eastern Virginia Medical School, Norfolk, Virginia","Thomas R Lee Center for Ocular Pharmacology, Eastern Virginia Medical School, Norfolk, Virginia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacology Section, Department of Physiologic Sciences, Eastern Virginia Medical School, Norfolk, Virginia","institution_ids":["https://openalex.org/I156802259"]},{"raw_affiliation_string":"Thomas R Lee Center for Ocular Pharmacology, Eastern Virginia Medical School, Norfolk, Virginia","institution_ids":["https://openalex.org/I156802259"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5078689711"],"corresponding_institution_ids":["https://openalex.org/I156802259","https://openalex.org/I4210140236"],"apc_list":null,"apc_paid":null,"fwci":5.0479,"has_fulltext":false,"cited_by_count":79,"citation_normalized_percentile":{"value":0.94935581,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"27","issue":"1","first_page":"23","last_page":"27"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10997","display_name":"Ocular Surface and Contact Lens","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10997","display_name":"Ocular Surface and Contact Lens","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10920","display_name":"Advanced Drug Delivery Systems","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13467","display_name":"Drug-Induced Ocular Toxicity","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/loteprednol-etabonate","display_name":"loteprednol etabonate","score":0.9459999799728394},{"id":"https://openalex.org/keywords/cyclosporine","display_name":"cyclosporine","score":0.7839999794960022},{"id":"https://openalex.org/keywords/topical-corticosteroids","display_name":"topical corticosteroids","score":0.8550000190734863},{"id":"https://openalex.org/keywords/stinging","display_name":"stinging","score":0.6179999709129333},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.6930000185966492},{"id":"https://openalex.org/keywords/medication-discontinuation","display_name":"drug discontinuation","score":0.7739999890327454},{"id":"https://openalex.org/keywords/induction-therapy","display_name":"induction therapy","score":0.8629999756813049},{"id":"https://openalex.org/keywords/ocular-surface","display_name":"ocular surface","score":0.7239999771118164},{"id":"https://openalex.org/keywords/fluorescein-staining","display_name":"fluorescein staining","score":0.7419999837875366},{"id":"https://openalex.org/keywords/conjunctival-hyperemia","display_name":"conjunctival hyperemia","score":0.9129999876022339},{"id":"https://openalex.org/keywords/tear-meniscus","display_name":"tear meniscus","score":0.949999988079071}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5964799523353577},{"id":"https://openalex.org/C2776148792","wikidata":"https://www.wikidata.org/wiki/Q3041498","display_name":"Eye disease","level":2,"score":0.514961302280426},{"id":"https://openalex.org/C118487528","wikidata":"https://www.wikidata.org/wiki/Q161437","display_name":"Ophthalmology","level":1,"score":0.452007919549942},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.3452257812023163}],"mesh":[{"descriptor_ui":"D000069559","descriptor_name":"Loteprednol Etabonate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000287","descriptor_name":"Administration, Topical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000305","descriptor_name":"Adrenal Cortex Hormones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000730","descriptor_name":"Androstadienes","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D002908","descriptor_name":"Chronic Disease","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015331","descriptor_name":"Cohort Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015352","descriptor_name":"Dry Eye Syndromes","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D016572","descriptor_name":"Cyclosporine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D016572","descriptor_name":"Cyclosporine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D058447","descriptor_name":"Eye Pain","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D058447","descriptor_name":"Eye Pain","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1089/jop.2010.0085","doi":"https://doi.org/10.1089/jop.2010.0085","is_oa":false,"landing_page_url":"https://doi.org/10.1089/jop.2010.0085","pdf_url":null,"source":{"id":"https://openalex.org/S192126995","display_name":"Journal of Ocular Pharmacology and Therapeutics","issn_l":"1080-7683","issn":["1080-7683","1557-7732","8756-3320"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Ocular Pharmacology and Therapeutics","raw_type":"journal-article"},{"id":"pmid:21133792","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21133792","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":17,"referenced_works":["https://openalex.org/W145780728","https://openalex.org/W1513824076","https://openalex.org/W1523354060","https://openalex.org/W1966009552","https://openalex.org/W1970158438","https://openalex.org/W1972554382","https://openalex.org/W2019045055","https://openalex.org/W2024921065","https://openalex.org/W2040915940","https://openalex.org/W2048559625","https://openalex.org/W2055370551","https://openalex.org/W2068160025","https://openalex.org/W2078269127","https://openalex.org/W2089996084","https://openalex.org/W2150621857","https://openalex.org/W2163991780","https://openalex.org/W2596391620"],"related_works":["https://openalex.org/W1999196223","https://openalex.org/W2911784697","https://openalex.org/W2327132310","https://openalex.org/W2621304441","https://openalex.org/W951740372","https://openalex.org/W4406149480","https://openalex.org/W4385456047","https://openalex.org/W4386206538","https://openalex.org/W3022171405","https://openalex.org/W3160144097"],"abstract_inverted_index":{"PURPOSE:":[0],"This":[1,74,288],"retrospective,":[2],"clinical":[3,9],"comparative":[4],"analysis":[5,75,289],"describes":[6,76,290],"differences":[7,244],"in":[8,156,235,245,271],"signs":[10],"and":[11,13,39,44,69,85,186,207,225,295,303],"symptoms":[12],"medication":[14,57],"tolerability":[15],"between":[16],"those":[17,40],"patients":[18,91,144,199],"who":[19,41,145],"receive":[20],"topical":[21,27,284],"corticosteroids":[22],"prior":[23,113],"to":[24,81,110,114,137,255,299],"initiation":[25],"of":[26,67,116,134,141,166,191,194,230,267],"cyclosporine":[28],"0.5%":[29,99],"emulsion":[30],"(tCSA)":[31],"therapy":[32,168,276],"for":[33,58,71,104,221,226],"chronic":[34],"dry":[35],"eye":[36],"disease":[37,247],"(CDED)":[38],"received":[42],"tCSA":[43,52,68,72,83,118,150,171,192,210,227,301],"were":[45,92,129,146],"not":[46],"first":[47],"induced":[48],"with":[49,95,258,273],"corticosteroid":[50,265],"drops.":[51],"is":[53,61],"the":[54,62,157,175,189,198,236,259,268],"only":[55,180],"approved":[56],"CDED.":[59],"Stinging":[60],"most":[63],"common":[64],"side":[65],"effect":[66],"reason":[70],"discontinuation.":[73,87,305],"an":[77],"effective":[78],"pharmacologic":[79,297],"means":[80],"reduce":[82,278,300],"stinging":[84,184,195,205,223,232,302],"subsequent":[86,281,304],"METHODS:":[88],"Thirty-six":[89],"consecutive":[90,143],"initially":[93,147],"treated":[94],"loteprednol":[96],"etabonate":[97],"(LE)":[98],"(Lotemax;":[100],"Bausch":[101],"&":[102],"Lomb)":[103],"a":[105,132,138,212,291],"period":[106,133],"ranging":[107],"from":[108,253,280],"2":[109,181],"16":[111],"months":[112,136,165],"institution":[115],"concomitant":[117,152,167],"(Restasis\u2122;":[119],"Allergan).":[120],"Clinical":[121],"parameters":[122],"(fluorescein":[123],"staining,":[124],"conjunctival":[125],"redness,":[126],"tear":[127],"meniscus)":[128],"compared":[130,257],"over":[131],"6":[135],"second":[139],"cohort":[140],"36":[142,176],"prescribed":[148],"continuous":[149],"without":[151,200,261],"LE":[153,158,162,177,201,237,274],"pretreatment.":[154,262],"Patients":[155,234],"pretreatment":[159,178,238],"group":[160,239,260],"discontinued":[161,188,209],"after":[163],"3-6":[164],"while":[169],"continuing":[170],"therapy.":[172],"RESULTS:":[173],"Of":[174,197],"patients,":[179],"developed":[182,204],"significant":[183,220,243],"(5.5%)":[185],"1":[187],"use":[190],"because":[193,229],"(2.8%).":[196],"pretreatment,":[202],"8":[203],"(22%)":[206],"3":[208],"as":[211],"result":[213],"(8.3%).":[214],"The":[215],"intergroup":[216],"P":[217],"value":[218],"was":[219],"severe":[222,231],"(<0.02)":[224],"discontinuation":[228],"(<0.04).":[233],"had":[240],"no":[241],"statistically":[242],"preenrollment":[246],"severity":[248],"or":[249],"demographics":[250],"(P":[251],"range":[252],"0.19":[254],"0.59)":[256],"CONCLUSION:":[263],"Topical":[264],"preparation":[266],"ocular":[269],"surface":[270],"CDED":[272],"induction":[275,294],"may":[277],"discomfort":[279],"long-term":[282],"maintenance":[283,296],"medications,":[285],"particularly":[286],"tCSA.":[287],"readily":[292],"available":[293],"strategy":[298]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2073701170","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":10},{"year":2015,"cited_by_count":7},{"year":2014,"cited_by_count":6},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":8}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
